Description of Research Expertise

My research focuses on inflammatory bowel disease specifically Crohn's disease and Ulcerative Colitis. My particular focuses include
1.) medical therapy of inflammatory bowel disease,
2.) safety of current medical therapy for IBD, and
3.) natural history of disease

Selected Publications

L. Peyrin-Biroulet, A. Dignass, W.J. Sandborn, K.G. Huang, M. Germinaro, R. Wilson, H. Zhang, B. Chen, M. Chen, T. Hisamatsu, B.G. Feagan, J. Panés, G.R. Lichtenstein.: The Effect of Guselkumab Induction Therapy on Inflammatory Biomarkers In Patients With Moderately To Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results Through Week 12. United European Gastroenterology Journal 2022; 10 (Supplement 8); October 2022 10 (8): 2022.

Lichtenstein GR: Spotlight on COVID-19 Gastroenterol Hepatol (N Y). : 2022.

Lichtenstein GR: Managing Patients With Helicobacter pylori Infection. Gastroenterol Hepatol (N Y). 18 (6): 2022.

Klapproth J and Lichtenstein Gary R.: Fistulizing Crohn’s Disease. In Pediatric Inflammatory Bowel Disease, 4th Edition. Eds. Mamula P, Markowitz JE, Baldassano R. Springer Publishers : 2022.

Bhavana Bhagya Rao, Abhik Bhattacharya, Lichtenstein Gary R.: New Non-anti-TNF- alpha Biologic Therapies for the Treatment of Inflammatory Bowel Disease. In Pediatric Inflammatory Bowel Disease, 4th Edition. Eds. Mamula P, Markowitz JE, Baldassano R. : 2022.

Lichtenstein GR.: Inflammatory Bowel Disease in Cecil’s Textbook of Medicine. Edited by Lee Goldman and Andrew I. Schafer. Elsevier Publisher. Philadelphia, PA. 25th Edition. 2022. Chapter : 2022.

Lichtenstein GR: Treatment for Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 18 (5): 231,2022.

Millie D. Long, Raymond K. Cross, Gary R. Lichtenstein, Jonathan Calkwood, Ashwini Pai Marc Pondel, Harris Ahmad, Lorna Charles, Ayanbola Elegbe, AnnKatrin Petersen, James K. Sheffield, Adil Javed, Jason K. Hou, Miguel D. Regueiro, Douglas C. Wolf, Alessandro Armuzzi: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS. Gastroenterology 2022; 162; 7 (Supplement S5-S6). Abstract 15. 162 (7): S5-S6,2022.

Jessica R. Allegretti, David T. Rubin, Brian Bressler, Kuan-Hsiang G. Huang, Nicole Shipitofsky, Matthew Germinaro, Hongyang Zhang, Jewel Johanns, Brian G. Feagan, William J. Sandborn, Bruce E. Sands, Tadakazu Hisamatsu, Gary R. Lichtenstein, Julian Panes, Axel Dignass: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12. Gastroenterology 2022; 162; 7 (Supplement S-963-964). Abstract Tu 1446 162 (7): 2022.

David T. Rubin, Stephan R. Vavricka, Alessandro Armuzzi, Marla C. Dubinsky, Ala I. Sharara, Irene Modesto, Fellmann Marc, Liguori Giusseppina, Lawendy Nervin, Cadatla Mary Jane, Lichtenstein, Gary R.: EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS PATIENTS WITH EXTRAINTESTINAL MANIFESTATIONS IN OCTAVE OPEN. Gastroenterology 2022; 162; 7 (Supplement S-979). Abstract Tu 1480 162 (7): 2022.

View all publications

Academic Contact Information

3400 Civic Center Boulevard
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
Phone: 215-349-8222
Patient appointments: 800-789-7366